gout
GOUT
Gout is a condition that resulted from deposition of monosodium urate crystals in various tissues (eg joints, connective tissue, kidney).
The patient experiences acute and chronic arthritis, soft tissue inflammation, tophus formation, gouty nephropathy and nephrolithiasis.
Primary hyperuricemia occurs when uric acid saturation arises without coexisting diseases or drugs that alter uric acid production or excretion, while secondary hyperuricemia is a condition where excessive uric acid production or diminished renal clearance occurs as a result of a disease, drug, dietary product or toxin. 

Gout References

  1. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-1446. doi: 10.1002/acr.21772. PMID: 23024028
  2. Schlesinger N. Diagnosis of gout: clinical, laboratory and radiologic finding. Am J Manag Care. 2005 Nov;11(Suppl 15):443-S450. PMID: 16300458
  3. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1447-1461. doi: 10.1002/acr.21773. PMID: 23024029
  4. Choi, HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol. 2010 Mar;22(2):165-172. doi: 10.1097/BOR.0b013e328335ef38. PMID: 20035225
  5. Tausche A, Jansen T, Schroder H, et al. Gout - current diagnosis and treatment. Dtsch Arztebl Int. 2009 Aug;106:549-555. doi: 10.3238/arztebl.2009.0549. PMID: 19795010
  6. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of acute arthritis of primary gout. Arthritis Rheum. 1977 Apr;20(3):895-900. PMID: 856219
  7. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies including Therapeutics (ESCISIT). Ann Rheum Dis. 2006 Oct;65(10):1312-1324. PMID: 16707532
  8. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006 Oct;65(10):1301-1311. PMID: 16707533
  9. Wortmann RL. Gout and hyperuricemia. In: Firestein GS, Budd RC, Harris ED Jr, et al. Kelley's Textbook of Rheumatology. 8th ed. Philadelphia, PA: Saunders, Elsevier; 2008.
  10. Jordan J, Cameron S, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout. http://www.mdconsult.com. 2007. Accessed 10 Jan 2012.
  11. Becker M. Clinical manifestation and diagnosis of gout. UpToDate. http://www.uptodate.com. Accessed 20 Jan 2012.
  12. National Institute for Health and Care Excellence (NICE). Pegloticase for treating severe chronic tophaceous gout. NICE. http://publications.nice.org.uk/pegloticase-for-treating-severe-debilitating-chronic-tophaceous-gout-ta291/about-this-guidance. Jun 2013.
  13. Becker M. Treatment of acute gout. UpToDate. http://www.uptodate.com.Accessed. Accessed 10 Jan 2012.
  14. Perez-Ruiz F, Dalbeth N, Urresola A, et al. Imaging of gout: findings and utility. Arthritis Research and Therapy. http://www.medscape.com. 2009. Accessed 10 Jan 2012.
  15. Malaysian Society of Rheumatology. Clinical Practice Guidelines: Management of gout. http://www.acadmed.org.my. Oct 2008. Accessed 10 Jan 2012.
  16. Becker MA. Treatment of acute gout. UptoDate website. http://www.uptodate.com/contents/treatment-of-acute-gout. Jun 2016.
  17. Li-Yu J, Salido EO, Manahan S, et al; in behalf of the Philippine Rheumatology Association. Philippine clinical practice guideline for the management of gout. Philippine College of Physicians (PCP) website. http://www.pcp.org.ph/documents/CPGs/PRA/Gout%20CPG%20Manuscript%20_PJIM%20072808_.pdf. 2016.
  18. Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 2015 Oct;67(10):2557-2568. http://onlinelibrary.wiley.com/doi/10.1002/art.39254/epdf. PMID: 26352873
  19. Hui M, Carr A, Cameron S, et al. The British Society for Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2017 Jul;56(7):e1-e20. doi: 10.1093/rheumatology/kex156. PMID: 28549177
  20. Paul BJ, James R. Gout: an Asia-Pacific update. Int J Rheum Dis. 2017 Apr;20(4):408-416. doi: 10.1111/1756-185X.13103. PMID: 28585370
  21. Qaseem A, Harris RP, Forciea MA. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017 Jan;166(1):58-68. doi: 10.7326/M16-0570. PMID: 27802508
  22. Chohan S. Gout and hyperuricemia. In: Kellerman R, Bope E. Conn's Current Therapy 2018; 2018. http://dx.doi.org/10.1016/B978-0-323-52769-9.00061-1. :281-284.
  23. Edwards NL. Crystal deposition diseases. In: Goldman L, Schafer A. Goldman-Cecil Medicine. 25th edition; 2016. http://dx.doi.org/10.1016/B978-1-4557-5017-7.00273-7. :1811-1816.e2.
  24. Bernstein S. New draft gout guideline released. The Rheumatologist. https://www.the-rheumatologist.org. 20 Nov 2019. Accessed 28 Feb 2020.
  25. Editorial. Hitting the target in gout. The Lancet Rheumatology. 2020 Jan;2(1). https://doi.org/10.1016/S2665-9913(19)30131-6.
  26. Li Q, Li X, Wang J, et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2019;9(8):e026677. doi: 10.1136/bmjopen-2018-026677. Accessed 28 Feb 2020. PMID: 31446403
  27. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020 May 11. doi: 10.1002/acr.24180. Accessed 22 May 2020. PMID: 32391934
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
22 hours ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.